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Abstract 
 
Alternative therapeutic strategies against Chlamydia trachomatis – the major cause of 
infectious blindness – are needed in times of raising antibiotic resistance.  
Previous studies showed that water filtered infrared A in combination with visible light 
(wIRA/VIS) reduced C. trachomatis infectivity in vitro, which was confirmed in this study.  
The secretion of pro-inflammatory cytokines upon wIRA/VIS irradiation led to the hypothesis, 
that these cytokines might be involved in the working mechanism of wIRA/VIS against 
C. trachomatis. This hypothesis was tested by IL-6, IL-8 and RANTES gene silencing or 
pharmaceutical inhibition of cytokines by Celastrol (IL-6, IL-8) or Maraviroc (RANTES). After 
excluding HeLa cell cytotoxicity and impact on chlamydial inclusion number, size and 
morphology, concentrations of 0.1 and 1 µM Celastrol and 10 and 20 µM Maraviroc were used 
in further experiments. Triple dose irradiation (24, 36, 40 hpi) significantly reduced chlamydial 
infectivity independent of cytokine inhibition. Therefore, other factors than host cell cytokine 
secretion must be involved in the reducing effect of wIRA/VIS on chlamydial infectivity.  
This study gives a first targeted insight into the working mechanism of wIRA/VIS in relation 
to an integral component of the host immune system and supports the potential of wIRA/VIS 
as a promising new device for trachoma treatment. 
Keywords 
 
Chlamydia trachomatis, wIRA/VIS, cytokine gene silencing, Celastrol, Maraviroc 
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Zusammenfassung 
 
Alternative Behandlungstrategien für Chlamydia trachomatis – dem wichtigsten Auslöser für 
infektiöse Blindheit - werden in Zeiten von Antibiotikaresistenzen dringend benötigt. 
Frühere in vitro Studien zeigten einen hemmenden Effekt von Wasser-gefilterter Infrarot 
Strahlung in Kombination mit sichtbarem Licht (wIRA/VIS) auf die Infektiosität von C. 
trachomatis sowie eine wIRA/VIS induzierte Freisetzung von inflammatorischen Zytokinen, 
was in dieser Studie bestätigt werden konnte.  
Aufgrund wiederholter Nachweise von IL-6, IL-8 und RANTES nach wIRA/VIS Bestrahlung 
wurde vermutet, dass diese Zytokine am Wirkmechanismus beteiligt sein könnten. Dies wurde 
durch IL-6, IL-8 und RANTES gene silencing und pharmakologischer Hemmung der Zytokine 
mittels Celastrol (IL-6, IL-8) und Maraviroc (RANTES) untersucht. Nach Ausschluss von 
Toxizität für HeLa Zellen und Auswirkungen auf Anzahl, Grösse und Morphologie der 
Chlamydieneinschlüsse, wurden 0.1 und 1 µM Celastrol und 10 bzw. 20 µM Maraviroc 
verwendet. Dreifachbestrahlungen (24, 36, 40 Stunden nach Infektion) reduzierten die 
Infektiosität der Chlamydien unabhängig von der Zytokinhemmung. Entsprechend müssen 
andere Faktoren als die Zytokinproduktion durch die Wirtszelle an der Wirkung von wIRA/VIS 
beteiligt sein.  
Diese Studie liefert einen ersten Einblick in den Wirkmechanismus von wIRA/VIS in 
Abhängigkeit einer selektiven Wirtsimmunabwehr. Des weiteren wird die Eignung von 
wIRA/VIS als mögliche Therapieoption für Trachompatienten bestärkt. 
 
 
Schlüsselwörter:  
 
Chlamydia trachomatis, wIRA/VIS, cytokine gene silencing, Celastrol, Maraviroc 
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Introduction 
 
Chlamydia trachomatis represents both, the most common bacterial sexually transmitted 
infection and the major cause of infectious blindness, worldwide (Hu et al., 2013). The 
primary frontline antibiotic used to treat ocular chlamydial infection and prevent trachoma is 
azithromycin , and current WHO recommendations constitute mass treatment with a single 
dose of azithromycin (WHO*). Antibiotic treatment can cause unwanted side-effects, is 
expensive and, particularly when used improperly, may lead to antibiotic resistance. Although 
resistance to azithromycin in C. trachomatis has not yet been reported, resistance in 
Streptococcus pneumoniae, a major cause of morbidity and mortality worldwide, increased 
after azithromycin mass treatment . Experiences from genital Chlamydia control programs 
suggest that early antimicrobial treatment interferes with the development of protective 
immune responses, leading to the “arrested immunity hypothesis” . Moreover, a break in the 
normal chlamydial developmental cycle can result in long-term infection  and such infections 
can cause a cascade of ongoing inflammatory-induced sequelae resulting in scarring and 
fibrosis. 
Chlamydiae are obligate intracellular bacteria with a complex developmental cycle 
comprising the infectious elementary body (EB) and the replicating reticulate body (RB). 
Under adverse environmental conditions, developing chlamydiae may enter a state referred to 
as persistence, more recently named the chlamydial stress response or the aberrant body (AB) 
phenotype . This AB chlamydial form is more resistant, or even refractory, to antibiotic 
treatment in vitro and in animal models . Since antibiotic side effects (cardiac 
events/azithromycin – Lu et al., 2015), risk of development of antibiotic resistance  and 
insufficient compliance during treatment (reviewed in Hammerschlag and Kohlhoff, 2012) 
represent serious drawbacks to current therapies, further therapeutic strategies are needed.  
Water-filtered infrared A (wIRA) is infrared radiation with a spectrum of 780-1400 nm, 
resulting from the light produced by a halogen bulb passing through a water cuvette to 
exclude wavelengths above 1400 nm and through a black filter to block visible light (VIS; 
Jung et al., 2012). Various clinical trials have shown that wIRA alone and in combination 
with visible light (wIRA/VIS) improves acute and chronic wound healing processes 
(Hoffmann, 2007). Moreover, two studies showed that wIRA/VIS treatment of abdominal 
wounds, before or after surgery, not only improved wound healing and oxygen partial 
pressure, but also reduced the rate of wound infections (Hartel et al., 2006; Künzli et al., 
2013). 
Our initial studies  investigated whether wIRA/VIS irradiation can reduce the number of 
chlamydial inclusions, and therefore diminish recovery of both intra- and extracellular 
infectious EBs, in cells infected with either human (genital serovar E of C. trachomatis) or 
animal (C. pecorum originating from a porcine abortion) chlamydial strains. A single 
application of wIRA/VIS irradiation at 40 hours post-infection (hpi) led to a significant (up to 
70%) reduction of infectivity in both strains of chlamydiae. Irradiation of host cells alone 
(HeLa or Vero) neither affected cell viability nor induced molecular markers of cytotoxicity . 
A triple application of irradiation (24, 36, 40 hpi) during the course of chlamydial infection 
further reduced chlamydial inclusion frequency in HeLa cells without inducing the 
unfavorable chlamydial persistence/chlamydial stress response. Quantitative analysis of 
cytokine and chemokine levels in supernatants of cell cultures subjected to triple irradiation 
revealed the release of a pro-inflammatory cytokines and chemokines upon irradiation or 
infection alone, or in combination .  
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We carried out a follow-up study , which investigated factors influencing the effect of 
wIRA/VIS on acute chlamydial infection, namely the impact of temperature, irradiation 
intensity, infectious dose and the efficacy of the VIS component. Our findings demonstrated 
that thermal as well as non-thermal effects of wIRA/VIS contribute to the inhibition of acute 
chlamydial infection. Additionally, VIS enhanced the inhibitory effect of wIRA on 
extracellular EBs, but the effect of irradiation was not influenced by chlamydial infection 
dose. The infectivity of mature chlamydial inclusions was significantly reduced upon 
wIRA/VIS application at all evaluated irradiation intensities, suggesting contribution of host 
cell factors to the anti-chlamydial effect at the late stage of the chlamydial developmental 
cycle . Experiments in permanent cell lines (Marti et al., 2014, 2015) were performed in the 
presence of the host cell protein synthesis inhibitor cycloheximide, whereas in an additional 
follow-up study  primary cell lines without cycloheximide supplementation were used.  
The abovementioned preliminary results encouraged our further evaluation of wIRA/VIS as a 
potential non-chemical treatment method for trachoma, the most common cause of infectious 
blindness worldwide. Therefore, we employed an in vitro model for ocular chlamydial 
infections using the ocular C. trachomatis serovar B strain to infect human conjunctival 
epithelial cells (HCjE) and evaluated the effects of wIRA/VIS on non-infected ocular 
structures in two ex vivo eye models . We demonstrated a significant wIRA/VIS-dependent 
reduction of chlamydial infectivity in HCjE. Unexpectedly, irradiation of HCjE prior to 
chlamydial infection was sufficient to inhibit chlamydial infectivity, suggesting the induction 
of a protective effect in wIRA/VIS-irradiated cells. Considering potentially harmful effects, 
wIRA/VIS irradiation did not reduce cell viability and post-treatment retinal damage was not 
observed. Additionally, vitreal temperature during wIRA/VIS irradiation did not markedly 
exceed physiological eye temperatures, suggesting that hyperthermia-related lesions are 
unlikely . Therefore, wIRA/VIS has shown considerable promise as a non-chemical method 
for the treatment of ocular chlamydial infections, namely blinding trachoma.  
Though preliminary studies indicate that thermal as well as non-thermal mechanisms are 
involved in the anti-chlamydial effect of wIRA/VIS , our understanding of the working 
mechanism of wIRA/VIS remains limited. In the first investigation into this working 
mechanism, Marti et al. (2014) detected increased cytokine and chemokine levels after 
wIRA/VIS irradiation of HeLa cells, an effect congruent with cytokine and chemokine release 
after C. trachomatis infection. This suggests a potential anti-chlamydial effect of wIRA/VIS 
based on immunological mimicry of chlamydial infections. In this study, we therefore aimed 
to more specifically evaluate the potential anti-chlamydial role of cytokines upon wIRA/VIS 
irradiation of C. trachomatis-infected HeLa cells. 
  
8 
 
Materials and methods 
 
2.1.  Host cells and media.  
HeLa cells (Homo sapiens cervix adenocarcinoma, CCL-2 ATCC) were cultured at 37°C with 
5% CO2 in growth culture medium for cell propagation. HeLa growth medium consisted of 
Minimal Essential Medium with Earle’s salts (MEM; GIBCO, Life Technologies, Carlsbad, 
CA, USA) supplemented with 4 mM GlutaMAX-I (GIBCO), 1% MEM Non-Essential Amino 
Acids (MEM NEAA; 100x, GIBCO) and 10% fetal calf serum (FCS; BioConcept, Allschwil, 
Switzerland). Medium used for infections contained the same components as growth medium, 
but was not supplemented with fetal calf serum. Cells were seeded directly into wells or on 
round glass coverslips (13 mm diameter, Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) in 24-well plates (Techno Plastic Products AG (TPP), Trasadingen, Switzerland). 
Infection experiments were performed 24 hours post-seeding or 59 hours post-seeding (Figure 
1). 
2.2.  Chlamydial strain.  
The genital strain Chlamydia trachomatis Serovar E (E/UW-5/CX kindly provided by Prof. R. 
V. Schoborg, Johnson City, TN, USA) was used for in vitro infection experiments. The isolate 
of the C. trachomatis strain was originally obtained from S.P. Wang and C.-C. Kuo 
(University of Washington, Seattle, WA, USA) and was propagated and harvestedas 
described previously . Briefly, chlamydia stocks were grown in HeLa cells (CCL-2, ATCC) at 
37°C in HeLa growth medium supplemented with 1 µg/ml cycloheximide (CHX) in an 
atmosphere of 5% CO2 for 46 hours, harvested and stored at -80°C in SPG medium (218 mM 
sucrose (Sigma-Aldrich, St. Louis, Missouri, USA), 3.76 mM KH2PO4 (Sigma-Aldrich), 7.1 
mM K2HPO4 (Merck Eurolab AG, Dietlikon, Switzerland) and 5 mM GlutaMAX-100 
(GIBCO). For infection, HeLa cells were seeded in 24-well plates and grown for 24 h at 
37°C, 5% CO2. Infections were performed at a multiplicity of infection (MOI) of 1 with 
subsequent centrifugation at 1000g for 1 h at 25°C as described previously (Rahn et al., 
2016).  
2.3.  wIRA/VIS irradiation.  
Cultures were irradiated three times at 24, 36 and 40 hours post-infection (hpi) with water-
filtered infrared A combined with visible light (wIRA/VIS) for 30 minutes using a wIRA 
radiator (hydrosun 750, Hydrosun GmbH, Müllheim, Germany) at intensities ranging from 
2340 - 3400 W/m2 (Figure 1). The resulting radiation spectrum ranges from 380 nm up to 
1400 nm. The irradiation procedure, cooling system and non-irradiated controls were the 
same as previously described (Jung et al., 2010; Marti et al., 2014). Briefly, 24-well plates 
were placed into a thermostat-controlled water bath (SC100, Thermo Fisher Scientific) set to 
37°C. Non-irradiated controls were placed on the same plates with suitable distance from 
irradiated conditions to avoid any irradiation influence. Irradiation was guided through optical 
fibers, reaching from the wIRA radiator (emission source) to the surface of the appropriate 
wells (irradiator point).  
2.4.  ELISA for IL-6, IL-8 and RANTES/CCL5.  
At 43 hpi, cell culture supernatants were collected, filtered through 0.1 µm syringe filters 
(Whatman Anotop, Sigma-Aldrich) and stored at -80°C until further processing. Cytokine 
levels were determined using human ELISA kits for IL-6(ID: KHC0061), IL-8 (ID: EH2IL8) 
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and RANTES (ID: EHRNTS) according to manufacturer’s instructions (Invitrogen™ (IL-6, 
RANTES) Carlsbad, California, USA,Thermo Fisher Scientific [IL-8]). Absorbance endpoint 
plate reading was performed on an Epoch 2 Microplate Spectrophotometer (BioTek® 
Winooski, VT, USA) at 450 nm wavelength, blank corrected and evaluated by the four-
parameter logistic ELISA curve fitting provided by elisaanalysis.com°. Cytokine 
concentrations were calculated in Microsoft Excel (Microsoft, Redmont, Washington, USA) 
as average ± STDEV and expressed as percentage of untreated controls. Since RANTES (also 
called CCL5) represents a chemokine in the group of cytokines, it will be further referred to 
as cytokine. 
2.5.  Study design.  
2.5.1. Infection experiments.  
The experiments were organized in four treatment groups: a) mock-infected and non-
irradiated, b) mock-infected and irradiated, c) C. trachomatis-infected and non-irradiated and 
d) C. trachomatis-infected and irradiated. Centrifugation-assisted infection of monolayers was 
performed as previously described (Rahn et al., 2016), with replacement of the inoculum with 
cycloheximide (CHX)-containing or CHX-free medium after infection (time point 0) 
depending on the experimental setting, and the infected cells were incubated for 40 hours, 
during which time three applications of irradiation were administered (Figure 1). Post-
irradiation, an incubation for three additional hours was applied and at 43 hpi, monolayers of 
all four groups were either fixed with methanol for immunofluorescence assay (IFA, on glass 
slides) or collected for titration by sub-passage as previously described (Marti et al., 2014). 
IFA was performed to label chlamydial LPS as previously described (Rahn et al., 2016) and 
chlamydial inclusion morphology was assessed. To determine mean inclusion size, 50 
randomly selected inclusions were examined per condition and area in μm2 was calculated 
using BonTec measuring and archiving software (BonTec, Bonn, Germany; Leonard et al., 
2015). Number of inclusion forming units (IFU) per mL was evaluated by sub-passage to 
determine infectious chlamydial particles as described in detail elsewhere (Rahn et al., 2016). 
IFU/mL was calculated and expressed as percentage of the corresponding control. Unless 
stated otherwise, experimental values were determined from duplicates, three independent 
experiments were performed, and data was expressed as the average ± standard deviation 
(STDEV) of three experimental values. Measurements were tested for normal distribution by 
Shapiro-Wilk test in R (R Core Team, 2016. R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria#) and statistical analysis 
was performed using Wilcoxon Rank Sum test with p values <0.05, <0.01 or <0.001 for 
significant differences.2.5.2.  Cycloheximide and irradiation experiments (Figure 1A).  
HeLa cells were seeded at a density of 2 x 105 cells/well for conditions without CHX or 
3 x 105 cells/well for CHX-exposed conditions and incubated for 24 hours before infection 
with C. trachomatis Serovar E at a MOI of 1. After centrifugation, infection media were 
replaced by cycloheximide-containing (1µg/ml, CHX) or cycloheximide-free (CHX-free) 
incubation medium and further processed as described above.  
2.6.  Silencing RNA (siRNA) for IL-6, IL-8 and RANTES: Transfection procedure, 
quantitative real-time PCR and irradiation experiments (Figure 1B).  
2.6.1.  Transfection procedure.  
Transfection of HeLa cells was performed according to Ambion manufacturer’s guidelines 
(Life technologies) in 24-well culture plates using 6.25 nM siRNA and 2 μl Lipofectamine® 
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RNAiMAX reagent for each siRNA (Thermo Fisher Scientific) under normoxic conditions in 
OptiMEM I reduced serum medium (Thermo Fisher Scientific). 
A mixture of two different silencer select siRNA for each cytokine (IL-6: ID: s7311, s7313; 
IL-8: ID: s7328, s7327; RANTES: ID: s12575, s12577) with a final concentration of 12.5 nM 
siRNA and 4 μl of Lipofectamine® RNAiMAX reagent and one silencer® select negative 
control (#1 siRNA) with a final concentration of 6.25 nM siRNA and 2 μl Lipofectamine® 
RNAiMAX reagent and dissolved in OptiMEM to a total volume of 400 µl per well was used. 
At the time of transfection, cell layers were reaching a confluency of 20 – 30%. After an 
incubation time of 5 hours, transfection reagents were replaced by usual HeLa growth 
medium without CHX for the further incubation of cells.  
Knockdown efficacy was confirmed by quantitative polymerase chain reaction (qPCR) at 24, 
48, 72 and 90 hours post-transfection in a preliminary experiment with two silenced wells 
(duplicates) per time point and cytokine (see 2.6.2). Transfection time point for irradiation 
experiments was 24 hours post-seeding and 35 hours prior to infection. 
2.6.2.  Quantitative real-time PCR.  
Total RNA was isolated using the RNeasy mini kit (ID: 74104, Qiagen, Venlo, Netherlands) 
and RNA content was measured by a NanoDrop Microvolume Spectrophotometer and 
Fluorometer (NanoDrop Technologies, LLC, Wilmington, DE, USA). 150 ng of extracted 
RNA was reverse transcribed into cDNA using the high-capacity cDNA reverse transcription 
kit (Applied Biosystems, Foster City, CA, USA) according to manufacturer’s guidelines 
(concentration of 15 ng/µl) on a Biometra Trio Thermocycler (Analytik Jena, Jena, Germany). 
PCR amplification was performed using the TaqMan™ Gene Expression Assays for IL-6 
(Hs00174131_m1), IL-8 (CXCL8, Hs00174103_m1) and RANTES (Hs00982282_m1) and 
the TaqMan® Fast Universal PCR Master Mix [2x] (Applied Biosystems) on a 7500-Fast ABI 
Thermocycler (Applied Biosystems). Cycle protocol was set according to manufacturer’s 
instructions.  
Silenced samples were run in triplicates (RANTES) or quadruplicates (IL-6, IL-8). Molecular-
biology-grade water (ThermoFisher Scientific) served as no template controls (NTC), which 
were run in duplicate, as were mismatch-silenced controls. Relative quantification of IL-6, IL-
8 and RANTES mRNA expression was determined relative to the endogenous control human 
Actin Beta (Human ACTB endogenous Control 4310881E (probe VIC, quencher TAMRA), 
Thermo Fisher Scientific) using the 2-ΔΔCT method. Data was calculated relative to the 
mismatch-silenced control mRNA levels using Microsoft Excel (Microsoft). 
2.6.3.  Irradiation experiments with transfected cells.  
HeLa cells were seeded at a density of 2.5 x 104 cells/well and incubated for 24 hours before 
transfection. Transfection was performed as stated in “transfection procedure” and cells were 
infected (or mock-infected) 35 hours post-transfection. Non-transfected cells (data not shown) 
and mismatch transfected cells served as controls. After centrifugation, infection media were 
replaced by CHX-free incubation medium and irradiation was carried out as described in 
sections 2.3 and 2.5.1. 
2.7.  Pharmaceutical inhibition of cytokines: cell viability assays, inhibitor 
concentration curves and irradiation experiments (Figure 1A).  
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Cell densities for all experiments with pharmaceutical inhibition of cytokines were 5 x 104 
cells/well. Ethanol (100%) was filtered through a 0.22 µm PES-membrane syringe filter 
(Techno Plastic Products AG (TPP)) and used as solvent control or to dilute pharmaceutic 
reagents. Based on the results of the cell viability assays (see below), ethanol concentrations 
over 0.5% were not used for further experiments. Celastrol 10 mg c0869 (Sigma Aldrich), an 
inhibitor of IL-6 and IL-8, was dissolved in 1 ml of 100% ethanol to a stock concentration of 
10 mg/ml. Maraviroc 10 mg 3756 (Tocris, Bristol, UK), a selective CCR5 receptor antagonist 
(and therefore an inhibitor of RANTES/CCL5), was dissolved in 1 ml of 100% ethanol to a 
stock concentration of 10 mg/ml. Stocks were re-filtered through 0.22 µm PES-membrane 
syringe filters (TPP) and then stored light-protected at -20°C until further use.  
2.7.1.  Cell viability assays.  
Cell viability assays were run in triplicates: Cells were incubated for 24 hours before adding a 
range of concentrations of ethanol, Maraviroc and Celastrol, depending on the experimental 
setting. Cell viability under ethanol incubation was tested by mixing 100% ethanol in a 1:1 
ratio with sterile Phosphate-Buffered Saline (PBS – GIBCO) and tested in HeLa growth 
medium at concentrations of 10%, 5%, 1%, 0.5%, and 0.1%. The resulting final 
concentrations of ethanol were 5%, 2.5%, 0.5%, 0.25% and 0.05%. Maraviroc was tested at 
concentrations of 20 µM, 10 µM, 1 µM and 0.1 µM and 0.103% ethanol in growth medium 
served as the Maraviroc solvent control. Celastrol was tested at concentrations of 25 µM, 
2 µM, 1 µM and 0.1 µM and 0.113% ethanol in growth medium served as the Celastrol 
solvent control. 10% Alamar blue dye (Invitrogen™) was added to cell cultures at 12, 24, 36 
and 45 hours (ethanol) or 48 hours (Maraviroc/Celastrol) after incubation. After three hours of 
incubation at 37°C, 2 x 200 µl, Alamar blue dye/culture medium was transferred into 96 well 
plates (generating two replicates from each well) and fluorescence was monitored using a 
Synergy HT Reader 270230 (BioTek®) at 530-nm excitation and 590-nm emission 
wavelength. Raw data were analyzed as mean ± STDEV in Microsoft Excel (Microsoft) and 
expressed as percentage of controls. If not stated differently, heat denatured cells served as 
positive controls. 
2.7.2.  Inhibitor concentration curves.  
To determine potential effects of the solvent (ethanol) and pharmaceutic inhibitors on 
C. trachomatis, infections were performed with supplemented media at the same 
concentrations as in the cell viability assays in triplicates, using 0.113% (Celastrol) or 0.103% 
(Maraviroc) ethanol-containing medium as corresponding mock-exposed controls.  
Briefly, C. trachomatis stocks were diluted in infection media supplemented with the 
appropriate concentrations of ethanol, Celastrol or Maraviroc, to MOI of 1 and centrifuged for 
1 hour at 25°C and 1000g (Rahn et al., 2016). After centrifugation, infection media were 
replaced by incubation medium with corresponding ethanol, Celastrol or Maraviroc 
concentrations. Cells were incubated for an additional 43 hours, then fixed with methanol as 
described previously (Marti et al., 2014). Inclusion size and morphology were analyzed as 
described above. Inclusion numbers were analyzed by counting inclusion numbers in 30 
randomly selected view fields at 200fold magnification. Mean ± STDEV for each 
concentration were calculated in Microscoft Excel (Microsoft) and expressed as percentage of 
untreated control (data not shown) or mock-exposed controls. 
2.7.3.  Irradiation experiments.  
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Celastrol concentrations of 1 µM and 0.1 µM, and Maraviroc concentrations of 20 µM and 
10 µM were chosen for irradiation experiments, based on the results of the cell viability 
assays and inhibitor concentration curves. Corresponding volumes of 100% ethanol were used 
as mock-exposed controls reaching final ethanol concentrations of 0.045% (1 µM and 0.1 µM 
Celastrol), 0.103% (20 µM Maraviroc) and 0.0515% (10 µM Maraviroc). Infection media and 
incubation media (CHX-free) were supplemented with the inhibitors or 100% ethanol and the 
same infection-, irradiation- and sampling steps as in previous irradiation experiments were 
performed (see above). 
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Results 
 
 3.1.  wIRA/VIS reduces chlamydial infectivity independent of cycloheximide (CHX) 
and reduces chlamydial inclusion size (Figure 2).  
To rule out potential effects of CHX, a eukaryote protein synthesis inhibitor, on the irradiation 
efficacy of wIRA/VIS, CHX-containing and CHX-free conditions were compared. 
Chlamydial infectivity after irradiation was significantly reduced, independent of CHX-
addition, resulting in remaining chlamydial infectivity of 10.14% (±0.81%) in CHX-
containing conditions (p-value<0.01) and 13.94% (±4.70%) in CHX-free conditions (p-
value<0.01; Figure 2A/B). The absolute chlamydial loads were significantly higher (p-value < 
0.01) in the CHX-supplemented conditions compared to the CHX-free ones. CHX-containing 
controls reached 6.56 x 107 ± 1.60 x 107 IFU/ml whereas the CHX-free conditions with 
1.18 x 106  ± 2.61 x 105 IFU/ml contained about 50 times less chlamydia. wIRA/VIS 
irradiated conditions with CHX (6.63 x 106 ± 1.43 x 106 IFU/ml) and without CHX 
(1.62 x 105 ± 4.67 x 104 IFU/ml) displayed the same significance level (p-value <0.01). 
Furthermore, irradiated inclusions were visibly smaller than those in the corresponding 
controls, which was further analyzed by comparing inclusion sizes of untreated controls with 
irradiated samples (n=9). Mean inclusion sizes of non-irradiated inclusions (305.47 µm2, 
±135.35 µm2) differed significantly from those of irradiated inclusions (238.59 µm2, 
±111.00 µm2) as visible in Figure 2C (CHX-free, p-value<0.001). 
3.2. Cytokine secretion (IL-6, IL-8, RANTES) upon wIRA/VIS treatment is 
independent of CHX (Figure 3).  
HeLa cell secretion of IL-6, IL-8 and RANTES into the culture media was analyzed upon 
infection, irradiation, or the combination of both, and compared to the mock-infected non-
irradiated control. In the absence of CHX (Figure 3A), IL-6 levels of 128.50% (±26.91%) 
upon irradiation, 149.96% (±30.98%) upon infection and 114.66% (±19.86%) upon the 
combination of both were observed. Upon irradiation, IL-8 levels increased to 195.62% 
(±97.25%) but were decreased upon C. trachomatis infection (95.46% ± 40.63%) and upon 
infection and irradiation (74.35% ±10.66%). RANTES secretion was increased in all three 
experimental conditions (118.27% ±25.82% upon irradiation, 115.24% ±28.53% upon 
infection, 107.22% ±20.16% upon the combination of both).  
In the presence of CHX (Figure 3B), IL-6 secretion was increased upon irradiation (106.24% 
±5.86%), infection (154.20%, ±18.28%) or the combination of both (140.70% ±22.14%). IL-8 
levels showed increases to 107.32% (±23.19%) upon irradiation, 134.58% (±50.57%) upon 
infection and 113.74% (±48.12%) upon the combination of both. And, finally, RANTES 
levels increased to 118.66% (±12.83%) upon irradiation alone, 125.47% (±20.23%) upon 
infection alone and 128.07% (±24.20%) after irradiation and infection. 
3.3. Gene silencing of IL-6, IL-8 and RANTES downregulates mRNA levels of all 
targets over a time period of 90 hours (Supplemental Figure 1).  
Decreases in mRNA levels were confirmed over a maximum time period of 90 hours post-
transfection to ensure that reduced mRNA levels of IL-6, IL-8 and RANTES were reached 
over the duration of the irradiation experiments. Mismatch negative silencer controls were 
evaluated at the same time points and set to 100% gene expression. Gene expression levels of 
IL-6 began decreasing by 24 hours (61.08% ±4.55%) and dropped to 32.50% of control 
(±17.28%) after 48 hours, 24.96% (±6.39%) after 72 hours and 27.80% (±0.30%) after 
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90 hours. mRNA levels of IL-8 dropped to 10.83% (±5.85%) within 24 hours and reached 
37.89% (±4.01%) of control after 48 hours, 43.44% (±2.35%) after 72 hours and 33.71% 
(±3.67%) after 90 hours. RANTES mRNA dropped to 24.87% (±12.46%) at 24 hours, 8.67% 
(±1.35%) at 48 hours, 7.71% (±1.43%) at 72 hours and 23.90% (±10.89%) at 90 hours post-
transfection.  
3.4. The reduction of chlamydial infectivity by wIRA/VIS is independent of IL-6, IL-8 
or RANTES gene silencing (Figure 4).  
Mismatch controls and target silenced cells were infected and irradiated as described above. 
Using sub-passage titer assays, chlamydial infectivity was calculated and expressed as percent 
of non-irradiated, mismatch silenced controls. Infection of IL-6 silenced cells resulted in 
chlamydial infectivity of 100.48% (±38.81%; p-value >0.05) of the control. wIRA/VIS 
irradiation at 24, 36 and 40 hpi resulted in a significant reduction of the chlamydial infectivity 
to 9.36% (±5.44%) for controls and 13.85% (±7.91%) in IL-6 gene silenced cells (p-values 
<0.01; Figure 4A).  
Infection of IL-8 silenced cells resulted in increased, but not significant (p>0.05) chlamydial 
loads of 142.61% (±36.79%). wIRA/VIS treatment of infected cells reduced chlamydial 
infectivity significantly to 9.36% (±5.44%) in controls and 17.04% (±15.04%) in IL-8 
silenced cells (p<0.01; Figure 4B).  
Infection of RANTES silenced cells resulted in chlamydial loads of 62.36% (±32.71%), 
which was not statistically significant compared to controls. Irradiation reduced chlamydial 
infectivity significantly (p<0.001) to 7.37% (±4.36%) in controls and 2.91% (±2.91%) in 
RANTES silenced conditions (n=5, Figure 4C). 
3.5.  Increasing ethanol and Celastrol concentrations decrease cell viability while 
Maraviroc concentrations up to 20 µM have no effect on cell viability (Supplemental 
Figure 2).  
Ethanol was employed as the diluent for Celastrol and Maraviroc in this study. Five ethanol 
concentrations (0.05%, 0.25%, 0.5%, 2.5% and 5.0%) were analyzed for potential impact on 
host cell viability at 12, 24, 36 and 45 hours post-incubation, as measured by Alamar blue 
assay. At all ethanol concentrations, decreased cell viability, compared to the control, was 
present at 24 hours post-incubation. However, cell viability at 36 and 45 hours post-
incubation was increased or slightly decreased at ethanol concentrations up to 0.5%, 
compared to controls, while concentrations of 2.5% and 5% reduced cell viability at all 
evaluated time points (Supplemental Figure 2A).  
Ethanol concentrations in Celastrol and Maraviroc dilutions reached 0.113% and 0.103%, 
respectively, and were reflected in the diluent controls for each inhibitor. Celastrol reduced 
cell viability at concentrations of 2 µM and 25 µM (Supplemental Figure 2B). Measured 
decrease in cell viability by Alamar blue assay was accompanied by the presence of increased 
numbers of rounded, detaching and floating cells and reduced cell confluency (data not 
shown). Therefore, Celastrol concentrations of 1 µM and 0.1 µM were chosen for irradiation 
experiments.  
Maraviroc, even at the high concentration of 20 µM and the longest incubation time of 48 
hours post-incubation, did not induce any change in cellular morphology (data not shown) or 
cell viability, thus, concentrations of 10 µM and 20 µM Maraviroc were chosen for irradiation 
experiments (Supplemental Figure 2C). 
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3.6.  Celastrol reduces C. trachomatis inclusion number and size, whereas Maraviroc 
only reduces inclusion number (Figure 5).  
As determined by IFA analysis of inclusion morphology, none of the evaluated ethanol, 
Celastrol or Maraviroc concentrations induced signs of persistence such as aberrant body 
formation (data not shown). At 43 hpi, inclusion sizes in controls were 376.05 µm2 
(±30.93 µm2) and 0.1 µM Celastrol incubated inclusions were of similar size, 353.86 µm2 
(±30.61 µm2). A significant reduction in inclusion size (241.79 µm2, ±20.00 µm2) was 
observed at a concentration of 1 µM Celastrol (p<0.001, Figure 5A). Inclusion numbers were 
significantly reduced at 1 µM Celastrol incubation (62.10% ±9.96%, p<0.001), whereas no 
significant difference was seen at a Celastrol concentration of 0.1 µM (101.38% ±12.56%; 
Figure 5B).  
None of the evaluated concentrations of Maraviroc led to a significant reduction of inclusion 
size compared to the control (Figure 5C). Inclusion numbers were significantly decreased at 
10 µM Maraviroc treatment to 84.45% (±3.05%, p-value<0.01) and at 20 µM (7.97% 
[±0.69%], p-value<0.001, Figure 5D). No significant differences from the control were 
observed at Maraviroc concentrations of 0.1 µM or 1 µM. 
3.7.  The reduction of chlamydial infectivity by wIRA/VIS is independent of 
pharmaceutical cytokine inhibition by Celastrol or Maraviroc (Figure 6).  
Infective chlamydial loads were determined by sub-passage titer assays and were calculated 
and expressed as percentage of the control. Utilizing inhibitor concentrations with minimal 
negative impact on cell viability (as described in sections 2.7.2 and 3.5) and associated with 
the observed inhibitor-dependent decreases in inclusion numbers discussed above, Celastrol 
incubation alone reduced chlamydial loads. Samples incubated with 0.1 µM Celastrol showed 
reduced infectivity of 84.47% (±14.51%) of the control, whereas 1 µM Celastrol resulted in a 
significant reduction (p<0.01) of chlamydial infectivity to 11.77% (±4.57%) of the control. 
Irradiation of Chlamydia-infected cells with wIRA/VIS further decreased chlamydial 
infectivity to 6.89% (±4.32%) for the controls, 6.15% (±2.28%) at 0.1 µM Celastrol, and to 
0.77% (±0.39%) at a concentration of 1 µM Celastrol. Statistical analysis showed significant 
differences for the reduction of chlamydial infectivity upon irradiation in all three tested 
conditions, with p-values of <0.01 (Figure 6A). 
C. trachomatis-infected inclusions incubated with 1 µM Celastrol were smaller than control 
inclusions (Figure 6B) and irradiation reduced inclusion sizes independent of Celastrol 
treatment (data not shown) as observed for control samples (Figure 2C).  
Maraviroc treatment resulted in chlamydial infectivity of 113.24% (±7.68%) at 10 µM and 
84.70% (±31.18%) at 20 µM concentrations, respectively, compared to the control. Irradiation 
with wIRA/VIS reduced chlamydial infectivity significantly in all evaluated conditions 
(p<0.01): Remaining infectivity after irradiation was 5.06% (±2.24%) in controls (n=6 for 
controls), 5.57% (±4.53%) in 10 µM and 6.46% (±5.19%) in 20 µM Maraviroc conditions 
(Figure 6C). Maraviroc incubation alone did not influence chlamydial inclusion morphology 
(Figure 6D). 
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Discussion 
 
Triple irradiation with wIRA/VIS during the course of C. trachomatis infection significantly 
reduces chlamydial infectivity in HeLa cells, which is in accordance with previous studies 
(Marti et al., 2014, 2015; Rahn et al., 2016). CHX, a host protein synthesis inhibitor, is known 
to promote chlamydial infection (Ripa, 1977; Wyrick, 2010), which was also confirmed in our 
study (see 3.1). Comparison of CHX-containing and CHX-free irradiated conditions revealed 
similar effects of wIRA/VIS treatment compared to the corresponding controls, indicating that 
wIRA/VIS irradiation is independent of CHX in our in vitro model (Figure 2).  
The secretion of pro-inflammatory cytokines in response to wIRA/VIS irradiation alone was 
independent of CHX incubation (Figure 3): in the presence or absence of CHX, wIRA/VIS-
dependent increase in secretion of IL-6, IL-8 or RANTES was, although not statistically 
significant, consistently observed. This was in accordance with previous results of cytokine 
regulation under wIRA/VIS irradiation (Marti et al., 2014). Dessus-Babus et al. (2000) and 
Leonard et al. (2017) reported increased IL-6 secretion after chlamydial infection under CHX-
influence, which we could confirm after comparing CHX-free and CHX-incubated conditions 
by t-test (data not shown). IL-8 secretion, however, was previously shown to decrease after 
CHX-treatment of Chlamydia-infected host cells (Dessus-Babus et al., 2000), which was not 
confirmed in our study.  
In this study, we did not report significantly increased levels of IL-6, IL-8 or RANTES upon 
chlamydial infection (alone or in combination with wIRA/VIS irradiation; Figure 3). The 
induction of IL-6 after C. trachomatis infection (in CHX-free conditions) has been observed 
by other authors (Buckner et al., 2013; Cheng et al., 2008; Dessus-Babus et al., 2000; 
Gervassi et al., 2004; Rasmussen et al., 1997). Similar results were obtained in multiple 
studies regarding IL-8 secretion  (Buchholz and Stephens, 2006; Buckner et al., 2013; Cheng 
et al., 2008; Gervassi et al., 2004; Rasmussen et al., 1997).  Dessus-Babus et al. (2000) also 
studied HeLa cells infected with C. trachomatis Serovar E and found increased IL-8 levels in 
the absence of CHX only after 48 hpi (not at earlier time points), but polarized cells were used 
in contrast to the non-polarized cells in our study. Even though Buckner et al. (2013) observed 
increases of IL-6 and IL-8, they did not reproduce the magnitude of up-regulation observed by 
Rasmussen et al. (1997).  
Increased RANTES levels after C. trachomatis infection was detected in investigations of the 
genital tract of mice infected with C. trachomatis (Maxion and Kelly, 2002). In contrast, 
Buckner et al. (2013) found decreased levels of RANTES in primary endocervical epithelial 
cells after infection with C. trachomatis Serovar D at 72 hpi.  
Regardless of CHX-dependent effects on cytokine responses to chlamydial infection, the 
increased cytokine levels after wIRA/VIS irradiation, even though not significant, were a 
constant finding for all investigated cytokines, and resembled the detected cytokine release 
pattern reported by . Considering that chlamydiae are a known trigger for cytokine secretion, 
their amount may also have a direct influence on cytokine secretion levels (Maxion and Kelly, 
2002). Even though all infection steps were performed with MOI=1 in our experiments, 
wIRA/VIS irradiation led to reduced chlamydial infectivity in the samples, which potentially 
influences the amount of secreted cytokines (Maxion and Kelly, 2002). Therefore, a 
theoretical correction of cytokine levels according to chlamydial infectivity was performed 
and resulted in significantly increased levels for all investigated cytokines under infection and 
irradiation treatment (data not shown). This supported our hypothesis that pro-inflammatory 
cytokines might play a role in wIRA/VIS-dependent anti-chlamydial effects.  
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Targeted cytokine suppression in HeLa cells was achieved by respective gene silencing 
(Supplemental Figure 1). The introduction of double-stranded RNAs into mammalian cells 
can lead to type I interferon (IFN) reactions involving IFN-α and -β (Matsumoto et al., 2004) 
and is known to evoke non-specific toxic effects in host cells (e.g. resulting in cell death or 
general shut-down of host cell protein synthesis) (Seok et al., 2018; Wadhwa et al., 2004), 
even though the used siRNAs in our study are considered to induce minimal side effects 
(manufacturer’s manuals). Interferons such as IFN-γ and host cell factors such as amino acid 
starvation or iron deprivation are known inducers of the so-called chlamydial stress response 
(Schoborg, 2011; Wyrick, 2010). In view of this, we qualitatively evaluated chlamydial 
inclusions upon chlamydial infection of target and mismatch control silenced HeLa cells, with 
regards to potential inclusion size reduction such as seen under DAMP influences (Leonard et 
al., 2015), or regarding morphological features indicative of aberrant body formation but 
neither effect was observed.  
Cytokine gene silencing did not have a significant effect on chlamydial infectivity (3.4) or cell 
viability (compared to mismatch silenced conditions).  
However, wIRA/VIS irradiation following gene silencing led to a reduction of chlamydial 
infectivity similar to that observed in irradiated mismatch silenced and non-transfected 
controls (Figure 4). This indicates that the wIRA/VIS anti-chlamydial effect is not abolished 
when mRNA transcription of pro-inflammatory cytokines such as IL-6, IL-8 and RANTES is 
suppressed.  
Next, we investigated the effect of pharmaceutical cytokine suppression on the wIRA/VIS-
dependent anti-chlamydial effect by using commercially available cytokine inhibitors. 
Celastrol is a natural substance derived from Thunder of God Vine (Tripterygium wilfordii) 
and used in traditional Chinese medicine (Kannaiyan et al., 2011; Venkatesha et al., 2016). 
Celastrol has been demonstrated to promote broad anti-inflammatory and anti-cancer effects 
(Kannaiyan et al., 2011; Venkatesha et al., 2016). In our study, we used Celastrol as an 
inhibitor for IL-6 and IL-8 secretion. In preliminary experiments, potential negative effects of 
Celastrol on HeLa cells were evaluated by performing cell viability assays (Supplemental 
Figure 2). Celastrol concentrations of 2 µM or higher reduced cell viability, therefore, 1 µM 
and 0.1 µM were chosen for subsequent irradiation experiments. Chiang et al. (2014) 
observed significantly reduced cell proliferation in prostate cancer cell lines from 0.1 µM 
concentration of Celastrol and were able to explain this finding by cell cycle inhibition and 
induced apoptosis. Shrivastava et al. (2015) observed similar findings in breast cancer cell 
lines at Celastrol concentrations ranging from 0.5 to 25 µM. Celastrol concentrations of 1 µM 
and 0.1 µM are considered effective for IL-6 and IL-8 inhibition according to one supplier’s 
manuals (SantaCruz, recommended concentrations for Celastrol as cytokine inhibitor: IC50 for 
IL-6 inhibition = 80 nM, IC50 for IL-8 210 nM+).  
First, we performed concentration curve analyses for Celastrol to gain insight into the effect 
of this inhibitor on chlamydial inclusion morphology, size and number (Figure 5). 
Morphology features indicative of persistence were not observed, but inclusion size and 
numbers were significantly reduced at 1 µM Celastrol concentration, compared to the control, 
whereas 0.1 µM concentration did not significantly change inclusion size or numbers. The 
addition of Celastrol decreased chlamydial infectivity, as assessed by sub-passage. This 
contrasts the results of cytokine inhibition by gene silencing, where inhibition of IL-6 or IL-8 
gene silencing did not significantly influence chlamydial infectivity. To our knowledge, no 
studies including Celastrol application and C. trachomatis have been performed until now. 
Infectivity upon wIRA/VIS irradiation was invariably reduced in all evaluated groups. In 
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conclusion, the anti-chlamydial effect of wIRA/VIS is independent of IL-6, IL-8 and 
pharmaceutical treatment with Celastrol (Figure 6).  
Maraviroc is a competitive CCR5 inhibitor approved for treating HIV/AIDS patients 
(Vangelista and Vento, 2018; Xu et al., 2014). CCR5 receptors are expressed on many 
inflammatory cells (e.g. T-cells, macrophages or dendritic cells) and serve as an important 
entry and binding site for the human immunodeficiency virus (Oliveira et al., 2014; Xu et al., 
2014). HeLa cells in vitro and cervical cancer samples ex vivo were demonstrated to express 
CCR5 (Che et al., 2016; Sales et al., 2014), though in ex vivo samples, CCR5 expression 
could be linked to the presence of leukocytes in the neoplastic areas (Sales et al., 2014). 
Natural ligands of CCR5 receptors include CCL3, CCL4 and RANTES (CCL5) (Oliveira et 
al., 2014; Vangelista and Vento, 2018) and Maraviroc has been shown to inhibit 
cytokine/chemokine effects at the CCR5 receptor (Dorr et al., 2005). In a preliminary 
experiment, Maraviroc concentrations of up to 20 µM were evaluated for potential negative 
effects on HeLa cells, which was ruled out (Supplemental Figure 2). Dorr et al. (2005) did not 
observe any negative effects on cell proliferation or cytotoxicity using Maraviroc 
concentrations up to 10 µM in PBMC and PM-1 cells. Concentration curve experiments 
evaluating inclusion morphology, size and number did not reveal changes indicative of 
chlamydial stress response or decreases in chlamydial inclusion size except for Maraviroc 
concentrations of 10 and 20 µM, which significantly reduced inclusion numbers compared to 
the control (Figure 5). To the author’s knowledge, there are no data available describing the 
interaction between Maraviroc and C. trachomatis or other chlamydial species. Sakthivel et 
al. (2008) attenuated the CCL5-CCR5 (RANTES-CCR5) axis by using anti-CCL5 antibodies 
in a mouse model with C. muridarum and revealed higher chlamydial loads in mice under 
anti-CCL5 treatment.  
Maraviroc incubation of C. trachomatis infected HeLa cells led to a mild, but not significant 
increase of chlamydial infectivity at 10 µM and decrease at 20 µM. The reduction of 
chlamydial infectivity upon wIRA/VIS irradiation, however, was consistently observed after 
blocking the CCR5 receptor by Maraviroc (Figure 6). To conclude, the wIRA/VIS effect does 
not depend on uninhibited RANTES/CCR5 function.  
Multiple studies, conducted in different models of chlamydial infection using wIRA alone or 
wIRA in combination with VIS irradiation, demonstrate that wIRA and wIRA/VIS have a 
stable and reproducible inhibitory effect on chlamydial infectivity (Marti et al., 2014, 2015; 
Rahn et al., 2016). Initial in vitro animal models using Vero cells and C. pecorum, as well as 
in vitro human models using HeLa cells and C. trachomatis Serovar E (genital model) or a 
combination of both, consistently demonstrated wIRA/VIS-dependent reduction of 
chlamydial inclusions and/or EBs (Marti et al., 2014, 2015). These previous experiments 
illustrated that wIRA and wIRA/VIS effects are independent of chlamydial strain or host cell 
line. Subsequently, primary cell lines (Human conjunctival epithelial cells (HCjE) were used 
in combination with C. trachomatis Serovar B to mimic an in vitro eye model, in which the 
same anti-chlamydial effects could be induced. Furthermore, irradiation of host cells (HCjE) 
prior to chlamydial infection led to a similar reduction of chlamydial infectivity as observed 
in previous studies, which indicates a wIRA-mediated impact on host cells possibly triggering 
a defense mechanism against chlamydial uptake (Rahn et al., 2016).  
Al-Ahmad et al. (2013) were the first authors, who investigated the combination of 
photodynamic therapy and wIRA/VIS (antimicrobial photodynamic therapy [aPDT]). 
Excellent antimicrobial effects of aPDT have been demonstrated in multiple studies, leading 
to severe reductions of bacterial loads in multiple bacterial species and even in biofilms (Al-
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Ahmad et al., 2013, 2015, 2016; Karygianni et al., 2014). In another study, blue light with an 
emission peak et 460 nm was sufficient to severely reduce loads of Aggregatibacter 
actinomycetemcomitans, a periodontal pathogen (Cieplik et al., 2014). As a potential working 
mechanism, activation of endogenous photosensitizers and resulting antimicrobial effects 
were suspected (Cieplik et al., 2014). Since 460 nm is included in the wIRA/VIS spectrum, 
activation of endogenous photosensitizers by particular wavelengths might be involved in the 
working mechanism. Wavelength-specific effects on cellular structures have been 
suspected/reported by multiple authors, e.g. Karu et al. (2001) reviewed in Hoffmann (2007). 
Cytochrome c oxidase has recently been identified as a photo-acceptor for irradiation in the 
range of visible and near-infrared radiation (Passarella and Karu, 2014) and potential working 
mechanism of wIRA/VIS might involve changes in redox potential, changes in biochemical 
activity, production of reactive oxygen species and photodynamic actions as suspected by 
Karu (1999). Nonetheless, no working mechanism regarding antimicrobial effects of 
wIRA/VIS has been identified until now.  
A previous study investigated cytokines as potential host cell factors being influenced by 
wIRA/VIS (Marti et al., 2014). In this study, we were able to gain a targeted insight into the 
host cellular immune response upon wIRA/VIS irradiation. We demonstrated that the 
reduction of chlamydial infectivity after wIRA/VIS irradiation is not abolished by 
pharmaceutical inhibition or gene silencing of host cell cytokines (IL-6, IL-8 and RANTES). 
Thus, factors other than host cell cytokine production must be involved in the working 
mechanism of wIRA/VIS. 
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Figures 
 
Figure 1: Experimental design.  
A) Experimental setting for pharmaceutical treatment: HeLa cells were seeded and cultured 
for 24 hours before infection with MOI=1 of C. trachomatis Serovar E. wIRA/VIS irradiation 
was performed at 24, 36 and 40 hours post-infection (hpi), for 30 minutes application time of 
irradiation, ranging between 2340 and 3400 W/m2. Cell densities were 5 x 104 for 
pharmaceutical inhibition of cytokines and corresponding controls and 3 x 105 for 
cycloheximide supplementation and 2 x 105 for controls, respectively. After three additional 
hours of incubation (43 hpi), sampling for further analyses (including direct IFA, titration by 
sub-passage, ELISA of supernatants) was performed.  
B) Experimental setting for gene silencing: After seeding and culture of HeLa cells (density 
2.5 x 104 cells/well), gene silencing (or negative control siRNA transfection) was performed, 
followed by an additional incubation time of 35 hours before infection with C. trachomatis 
Serovar E at MOI=1. Irradiation and sampling time points were the same as described in A.  
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Figure 2: wIRA/VIS reduces chlamydial infectivity independent of cycloheximide (CHX) 
and reduces chlamydial inclusion size.  
According to figure 1, irradiation experiments were performed. Experiments were run either 
without (Figure 2A) or with (Figure 2B) cycloheximide (CHX) supplementation following 
chlamydial infection. Chlamydial infectivity upon titration by subpassage was determined as 
IFU/ml and is presented in the black bars as percentage of non-irradiated controls (empty 
bars). Figure 2C demonstrates the reduction of chlamydial inclusion size upon wIRA/VIS 
irradiation (n=9). Significance levels are marked with asterisks: * for p<0.05, ** for p<0.01 
and *** for p<0.001.  
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Figure 3: Cytokine secretion of IL-6, IL-8 and RANTES upon wIRA/VIS treatment is 
independent of CHX.  
After seeding, infection and irradiation without (A) or with (B) cycloheximide (CHX) 
supplementation, supernatants were collected for IL-6, IL-8 and RANTES ELISA analysis at 
43 hpi. IL-6, IL-8 and RANTES levels are expressed according to the experimental groups as 
percentage of non-irradiated controls. Treatment groups include mock-infected and non-
irradiated conditions (controls, empty bars), mock-infected and irradiated (bright grey bars), 
C. trachomatis-infected and non-irradiated (dark grey bars) and C. trachomatis-infected and 
irradiated (black bars) conditions.  
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Figure 4: Gene silencing of IL-6 and IL-8 does not influence the anti-chlamydial effect of 
wIRA/VIS.  
After seeding, gene silencing for IL-6 (A), IL-8 (B) and RANTES (C), infection with 
C. trachomatis serovar E and irradiation, monolayers were sampled for titration by sub-
passage to evaluate chlamydial infectivity. Chlamydial infectivity, as IFU/ml, was determined 
and expressed as percentage of non-irradiated control samples. Chlamydial infectivity was 
significantly decreased in all irradiated conditions, independent of gene silencing. Figures 
show results of three independent experiments for IL-6 and IL-8 silencing and five 
experiments for RANTES gene silencing. Significance levels are marked with asterisks: * for 
p<0.05, ** for p<0.01 and *** for p<0.001. 
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Figure 5: Celastrol significantly reduces C. trachomatis inclusion number and size, 
whereas Maraviroc reduces the inclusion number.  
C. trachomatis infection and supplementation with Celastrol (A, B) and Maraviroc (C, D) 
were performed in parallel. After 43 hours of incubation, monolayers were fixed with 
methanol and immunofluorescence stained. Inclusion sizes (A, C) and numbers (B, D) were 
analyzed by either measurement of inclusions or counting of inclusion numbers per fields 
(200x magnification) relative to controls (ctrl). Significance levels are marked with asterisks: 
* for p<0.05, ** for p<0.01 and *** for p<0.001. 
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Figure 6: The pharmaceutical inhibition of IL-6, IL-8 or RANTES does not abolish the 
anti-chlamydial effect of wIRA/VIS on C. trachomatis.  
After seeding, infection, Celastrol (A, B) or Maraviroc (C, D) supplementation and 
irradiation, monolayers were either fixed with methanol for direct IFA analysis (B, D) or 
sampled for titration by sub-passage to determine chlamydial infectivity (A, C). Chlamydial 
infectivity was calculated as IFU/ml and expressed as percentage of the non-irradiated control 
(ctrl). Bars represent results of three independent experiments. For Maraviroc (C), the two 
investigated concentrations were tested in separate experimental settings and results were 
summarized into one figure, resulting in n=6 for the control (ctrl). Significance levels are 
marked with asterisks: ** for p-values <0.01.  
To assess potential morphological changes under pharmaceutical inhibition, direct IFA of 
monolayers was performed and analyzed with regards to inclusion morphology and size. 
Celastrol 1 μM alone led to significantly smaller inclusions compared to controls (ctrl) (B), 
whereas Maraviroc did not alter inclusion morphology (D).  
 
 
  
26 
 
Supplemental Figure 1: Gene silencing of IL-6, IL-8 and RANTES leads to sufficient 
reductions of mRNA levels over experimental time.  
HeLa cells were seeded, incubated for 24 hours and transfected with siRNA for IL-6, IL-8 and 
RANTES gene silencing or mismatch siRNA. After an incubation of 5 hours, media were 
replaced by HeLa growth medium. Sampling of monolayers for RNA isolation, reverse 
transcription and quantitative real time PCR was performed at 24, 48, 72 and 90 hours post-
transfection. Reduction of mRNA levels compared to mismatch-transfected samples and 
endogenous controls (actin beta) was evaluated by the 2-ΔΔCT method and mRNA levels are 
expressed as percentage of mismatch controls. IL-6 and IL-8 samples were run in 
quadruplicates, RANTES samples in triplicates of two replicate samples.  
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Supplemental Figure 2: Increasing ethanol and Celastrol concentrations lead to reduced 
cell viability, whereas Maraviroc concentrations up to 20 µM did not reduce cell viability.  
Cell viability assays were performed by seeding HeLa cells (5 x 104 cells/well) followed by 
24 hours of incubation and replacement of incubation media by ethanol (A), Celastrol (B) or 
Maraviroc (C) supplemented media at indicated concentrations. Cell viability was assessed at 
12, 24, 36 and 45 hours (ethanol) or 48 hours (Celastrol and Maraviroc as represented by 
empty bars in Figure 2B and 2C). Cell viability is expressed as percentage of non-treated 
HeLa cells (A - control) or as percentage of ethanol-incubated HeLa cells (diluent-controls; B, 
C).  
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